Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
66.64 (1y: -4%)
Market Cap 2.46 B P/E(ttm) 22.00
Enterprise Value 2.15 B P/B 3.64
TECH- NAS (USA)
Techne Corporation
  • Currently 4/5
Business Predictability Rank: 4-Star (On Watch)
Back Testing Results:
Average gain of all 4-Star stocks: 9.8% per year.
% of Stocks that are in still loss if held for 10yrs: 8%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$66.64
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
TECH's Cash to Debt is ranked higher than
75% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.24 vs. TECH: No Debt )
TECH' s 10-Year Cash to Debt Range
Min: 3.03   Max: No Debt
Current: No Debt
Equity to Asset 0.754
TECH's Equity to Asset is ranked higher than
78% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.53 vs. TECH: 0.754 )
TECH' s 10-Year Equity to Asset Range
Min: 0.58   Max: 0.92
Current: 0.75
0.58
0.92
Interest Coverage No Debt
TECH's Interest Coverage is ranked higher than
74% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. TECH: No Debt )
TECH' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 38.96
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry		 vs
history
Operating margin (%) 52.80
TECH's Operating margin (%) is ranked higher than
99% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 6.00 vs. TECH: 52.80 )
TECH' s 10-Year Operating margin (%) Range
Min: 37.9   Max: 58.1
Current: 52.8
37.9
58.1
Net-margin (%) 35.7
TECH's Net-margin (%) is ranked higher than
95% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. TECH: 35.7 )
TECH' s 10-Year Net-margin (%) Range
Min: 20.7   Max: 40.8
Current: 35.7
20.7
40.8
ROE (%) 16.7
TECH's ROE (%) is ranked higher than
87% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. TECH: 16.7 )
TECH' s 10-Year ROE (%) Range
Min: 13.1   Max: 24.7
Current: 16.7
13.1
24.7
ROA (%) 15.6
TECH's ROA (%) is ranked higher than
94% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. TECH: 15.6 )
TECH' s 10-Year ROA (%) Range
Min: 11.4   Max: 22.4
Current: 15.6
11.4
22.4
ROC (Joel Greenblatt) (%) 122.60
TECH's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 12.10 vs. TECH: 122.60 )
TECH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 59.6   Max: 122.6
Current: 122.6
59.6
122.6
Revenue Growth (%) 5.1
TECH's Revenue Growth (%) is ranked higher than
71% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 5.1 )
TECH' s 10-Year Revenue Growth (%) Range
Min: 4.4   Max: 10.7
Current: 5.1
4.4
10.7
EBITDA Growth (%) 3.7
TECH's EBITDA Growth (%) is ranked higher than
78% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 3.7 )
TECH' s 10-Year EBITDA Growth (%) Range
Min: 3.7   Max: 13.5
Current: 3.7
3.7
13.5
EPS Growth (%) 2.3
TECH's EPS Growth (%) is ranked higher than
78% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 2.3 )
TECH' s 10-Year EPS Growth (%) Range
Min: 2.3   Max: 26.1
Current: 2.3
2.3
26.1
» TECH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

TECH Guru Trades in Q2 2012

Steven Cohen 3,811 sh (New)
Columbia Wanger 530,000 sh (+1.92%)
Bill Frels 386,017 sh (+1.22%)
Chuck Royce 257,400 sh (unchged)
Ron Baron 1,066,630 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Jim Simons 820,100 sh (-1%)
Chris Davis 28,971 sh (-7.86%)
Jeremy Grantham 25,100 sh (-12.54%)
» More
Q3 2012

TECH Guru Trades in Q3 2012

Joel Greenblatt 24,249 sh (New)
Bill Frels 427,538 sh (+10.76%)
Jim Simons 866,100 sh (+5.61%)
Columbia Wanger 556,700 sh (+5.04%)
Steven Cohen Sold Out
Ron Baron 1,054,780 sh (-1.11%)
Chris Davis 26,916 sh (-7.09%)
Jeremy Grantham 19,400 sh (-22.71%)
Chuck Royce 186,400 sh (-27.58%)
» More
Q4 2012

TECH Guru Trades in Q4 2012

Steven Cohen 7,729 sh (New)
Paul Tudor Jones 3,400 sh (New)
Columbia Wanger 639,700 sh (+14.91%)
Jim Simons 945,800 sh (+9.2%)
Bill Frels 432,787 sh (+1.23%)
Jeremy Grantham 21,700 sh (unchged)
Chuck Royce 186,400 sh (unchged)
Ron Baron 1,053,980 sh (-0.08%)
Chris Davis 23,820 sh (-11.5%)
Joel Greenblatt 19,562 sh (-19.33%)
» More
Q1 2013

TECH Guru Trades in Q1 2013

Joel Greenblatt 45,922 sh (+134.75%)
Chuck Royce 341,300 sh (+83.1%)
Bill Frels 693,067 sh (+60.14%)
Paul Tudor Jones 5,100 sh (+50%)
Chris Davis 33,973 sh (+42.62%)
Jeremy Grantham 22,100 sh (+1.84%)
Ron Baron 1,053,980 sh (unchged)
Columbia Wanger 630,700 sh (-1.41%)
Jim Simons 919,400 sh (-2.79%)
Steven Cohen 4,153 sh (-46.27%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 134.75%0.09%$66.48 - $71.68 $ 66.64-3%45922
Joel Greenblatt 2012-09-30 New Buy0.12%$67 - $75.98 $ 66.64-7%24249
Joel Greenblatt 2012-06-30 Sold Out 0.06%$64.98 - $74.23 $ 66.64-2%0
Chuck Akre 2012-03-31 Sold Out 0.53%$66.13 - $71.99 $ 66.642%0
John Hussman 2012-03-31 Sold Out 0.05%$66.13 - $71.99 $ 66.642%0
Joel Greenblatt 2012-03-31 Add 47.81%0.02%$66.13 - $71.99 $ 66.642%8941
John Hussman 2011-12-31 New Buy0.05%$62.37 - $73.55 $ 66.64-2%44000
Joel Greenblatt 2011-12-31 New Buy0.05%$62.37 - $73.55 $ 66.64-2%6049
Joel Greenblatt 2011-09-30 Sold Out 0.05%$67.45 - $85.13 $ 66.64-10%0
Ruane Cunniff 2011-09-30 Sold Out 0.0019%$67.45 - $85.13 $ 66.64-10%0
Ruane Cunniff 2011-06-30 New Buy$72.65 - $83.16 $ 66.64-15%2540
Joel Greenblatt 2011-03-31 New Buy0.1%$65.67 - $73.26 $ 66.64-4%4852
Chuck Akre 2010-12-31 New Buy0.69%$59.42 - $68.02 $ 66.647%50000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 22.00
TECH's P/E(ttm) is ranked higher than
53% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 24.00 vs. TECH: 22.00 )
TECH' s 10-Year P/E(ttm) Range
Min: 16.78   Max: 108.43
Current: 22
16.78
108.43
P/B 3.64
TECH's P/B is ranked lower than
72% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. TECH: 3.64 )
TECH' s 10-Year P/B Range
Min: 3.28   Max: 20.64
Current: 3.64
3.28
20.64
P/S 7.95
TECH's P/S is ranked lower than
86% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. TECH: 7.95 )
TECH' s 10-Year P/S Range
Min: 5.69   Max: 27.43
Current: 7.95
5.69
27.43
PFCF 21.85
TECH's PFCF is ranked lower than
54% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 20.43 vs. TECH: 21.85 )
TECH' s 10-Year PFCF Range
Min: 17.73   Max: 401.84
Current: 21.85
17.73
401.84
EV-to-EBIT 13.46
TECH's EV-to-EBIT is ranked higher than
70% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 19.44 vs. TECH: 13.46 )
TECH' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 73.1
Current: 13.46
10.4
73.1
PEG 3.93
TECH's PEG is ranked lower than
76% of the 46 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. TECH: 3.93 )
TECH' s 10-Year PEG Range
Min: 1.07   Max: 5.36
Current: 3.93
1.07
5.36
Shiller P/E 21.78
TECH's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. TECH: 21.78 )
TECH' s 10-Year Shiller P/E Range
Min: 20.88   Max: 52.05
Current: 21.78
20.88
52.05

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 1.77
TECH's Dividend Yield is ranked higher than
83% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 1.77 )
TECH' s 10-Year Dividend Yield Range
Min: 0.39   Max: 1.82
Current: 1.77
0.39
1.82
Dividend Payout 0.3
TECH's Dividend Payout is ranked lower than
59% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 0.33 vs. TECH: 0.3 )
TECH' s 10-Year Dividend Payout Range
Min: 0.27   Max: 0.37
Current: 0.3
0.27
0.37
Dividend growth (3y) 10.3
TECH's Dividend growth (3y) is ranked higher than
97% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 10.3 )
TECH' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 10.3
Current: 10.3
0
10.3
Yield on cost (5-Year) 1.80
TECH's Yield on cost (5-Year) is ranked higher than
81% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 1.80 )
TECH' s 10-Year Yield on cost (5-Year) Range
Min: 0.39   Max: 1.82
Current: 1.8
0.39
1.82
Share Buyback Rate 0.6
TECH's Share Buyback Rate is ranked higher than
88% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 0.6 )
TECH' s 10-Year Share Buyback Rate Range
Min: 1.5   Max: 0.1
Current: 0.6

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 10.9
TECH's Price/Net Cash is ranked lower than
54% of the 69 Companies
in the Global Medical Devices industry.

( Industry Median: 10.90 vs. TECH: 10.9 )
TECH' s 10-Year Price/Net Cash Range
Min: 12.2   Max: 132.7
Current: 10.9
12.2
132.7
Price/Net Current Asset Value 45.8
TECH's Price/Net Current Asset Value is ranked lower than
84% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 13.30 vs. TECH: 45.8 )
TECH' s 10-Year Price/Net Current Asset Value Range
Min: 51.2   Max: 162.5
Current: 45.8
51.2
162.5
Price/Tangible Book 4.6
TECH's Price/Tangible Book is ranked lower than
66% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 3.00 vs. TECH: 4.6 )
TECH' s 10-Year Price/Tangible Book Range
Min: 4.5   Max: 26.2
Current: 4.6
4.5
26.2
Price/DCF (Projected) 1.3
TECH's Price/DCF (Projected) is ranked higher than
55% of the 73 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. TECH: 1.3 )
TECH' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 3
Current: 1.3
1.3
3
Price/Median PS Value 0.8
TECH's Price/Median PS Value is ranked higher than
68% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 1.00 vs. TECH: 0.8 )
TECH' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 2.6
Current: 0.8
0.8
2.6
Price/Peter Lynch Fair Value 3.3
TECH's Price/Peter Lynch Fair Value is ranked lower than
980% of the 25 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. TECH: 3.3 )
TECH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.4   Max: 3.7
Current: 3.3
1.4
3.7
Price/Graham Number 2.1
TECH's Price/Graham Number is ranked lower than
57% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. TECH: 2.1 )
TECH' s 10-Year Price/Graham Number Range
Min: 2   Max: 11
Current: 2.1
2
11
Earnings Yield (Greenblatt) 7.40
TECH's Earnings Yield (Greenblatt) is ranked higher than
77% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. TECH: 7.40 )
TECH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.4   Max: 9.6
Current: 7.4
1.4
9.6
Forward Rate of Return (Yacktman) 7.88
TECH's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 214 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. TECH: 7.88 )
TECH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 8.5   Max: 21.7
Current: 7.88
8.5
21.7

Business Description

Techne Corporation is engaged in the development, manufacture and sale of biotechnology products and hematology calibrators and controls. These activities are conducted domestically through its wholly-owned subsidiaries, Research and Diagnostic Systems, Inc., Boston Biochem, Inc. and BiosPacific, Inc. The Company develops, manufactures and distributes biotechnology products in Europe through its wholly-owned U.K. subsidiaries, R&D Systems Europe Ltd. (R&D Europe) and Tocris Holdings Limited (Tocris). R&D Europe has a sales subsidiary, R&D Systems GmbH, in Germany and a sales office in France. The Company distributes biotechnology products in China through its wholly-owned subsidiary, R&D Systems China Co., Ltd. (R&D China). R&D China has a sales subsidiary, R&D Systems Hong Kong, Ltd., in Hong Kong. The Company has two reportable segments based on the nature of its products. R&D Systems' Biotechnology Division, R&D Europe, Tocris, R&D China, BiosPacific and Boston Biochem operating segments are included in the biotechnology reporting segment. The Company's biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company, through its biotechnology segment, is one of the world's suppliers of specialized proteins, such as cytokines and related reagents, to the biotechnology research community. These valuable proteins are produced in minute amounts by different types of cells and can be isolated from these cells or synthesized through recombinant DNA technology. The Company's hematology reporting segment, which consists of R&D Systems' Hematology Division, develops and manufactures hematology controls and calibrators for sale world-wide. Hematology controls and calibrators are products derived from various cellular components of blood which have been stabilized. Control and calibrator products can be utilized to ensure that hematology instruments are performing accurately and reliably. The Company offers a range of hematology controls and calibrators for both impedance and laser type cell counters. The Company is engaged in ongoing research and development in all of its major product lines: controls and calibrators (hematology) and cytokines, antibodies, assays and related products (biotechnology). The main hematology control competitors for the Company's hematology retail products are Abbott Diagnostics, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Streck, Inc., Siemens Healthcare Diagnostics Inc. and Sysmex Corporation. The Company's operations are subject to regulation by various U.S. federal, state and international agencies.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:TE1.Germany
» More Articles for TECH

Headlines

Articles On GuruFocus.com
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
10 High Margin Healthcare Dividend Shares Jan 02 2012 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 
Techne Corp. Reports Operating Results (10-Q) Feb 08 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial